Sanofi SA (ADR) (SNY), Merck & Co., Inc. (MRK): Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

Page 1 of 2

Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk of this disease, the incidence of which has grown 30-fold during the last 50 years.

Poised for gains from brewing remedies

The good news is, in about two years, the world will possibly have its first dengue vaccine. The big pharma Sanofi SA (ADR) (NYSE:SNY) is now conducting two late-stage human testings involving some 45,000 participants in Asia and Latin America. The results are expected either late 2013 or in 2014.

In addition, there are other vaccine types in the most advanced stage of development. Phase I trial, for instance, has been completed on a vaccine developed by the privately held Hawaii Biotech. New Jersey-based Merck & Co., Inc. (NYSE:MRK) now owns the rights on this vaccine, which it acquired in 2010.

The U.K.-based GlaxoSmithKline plc (ADR) (NYSE:GSKis also in pursuit of a vaccine type similar to Sanofi SA (ADR) (NYSE:SNY)’s. It has conducted several clinical studies on this vaccine, including those done in the U.S., Puerto Rico, and Thailand. The company has also partnered with the Fiocruz, a Brazilian foundation, for the development and manufacturing of the vaccine for dengue in Brazil where this disease is a major health concern.

A prop-up for a weak quarter

Sanofi SA (ADR) (NYSE:SNY)An advance in Glaxo’s pursuit of a dengue vaccine should provide tailwinds to the company, which has been reaping some negative market sentiment due to a recent bribery scandal in China and generics eating into its market share. Reporting a 4% core EPS gain on 2% sales growth in the second quarter, Glaxo acknowledged that the result of the bribery investigation is likely to impact its subsequent performance in China.

Certainly, a step up of the dengue vaccine in Merck & Co., Inc. (NYSE:MRK)’s pipeline can also burnish this company’s allure among investors who were turned off recently by a staggering 48% drop in company earnings and 10% decline in revenue during the second quarter primarily due to competition from generics.

Like Glaxo and Merck & Co., Inc. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY) has also been feeling the pinch of generic competition. In the second quarter, sales lost to generics resulted in a 6.3% decline in Sanofi’s total sales and an 18.5% drop in business EPS.

Despite their recent weak results, a strong rebound from this triumvirate can’t be discounted. Besides their dengune vaccines under development, they also have other drugs in the pipeline which are potential earning catalysts.

For the near term, Merck & Co., Inc. (NYSE:MRK) hopes to draw strength from about 40 drugs in its pipeline, out of which six are close to market launch. Just this July, the U.S. FDA has accepted the new drug application for Merck’s anti thrombotic candidate, vorapaxar, for standard testing. Speculations are also rife that the company is eyeing to bolster its product entries in the lucrative oncology medicines through an acquisition.

GlaxoSmithKline plc (ADR) (NYSE:GSK), for its part, flaunts new respiratory products coming onto the market, one of which is the recently FDA-approved Breo Ellipta, which analysts believe to have a peak potential of $1.3 billion sales in the U.S. alone. Likewise potent in earnings possibility is the company’s protein-based therapy, ofatumumab, for multiple sclerosis, now on Phase II trial.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!